Unlocking the Future: Hemogenyx Pharmaceuticals PLC Welcomes New Ordinary Shares and a Fresh ISIN!

Admission of New Ordinary Shares and New ISIN

LONDON, UNITED KINGDOM / ACCESSWIRE / December 10, 2024 / Hemogenyx Pharmaceuticals plc (“Hemogenyx Pharmaceuticals” or the “Company”)(LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood diseases, wishes to provide a further update on the admission of the New Ordinary Shares (as defined below) further to the passing of all resolutions at its Extraordinary General Meeting (the “Meeting”) held on 9 December 2024. At the Meeting, resolutions were passed to approve the subdivision and reclassification of the Company’s existing 1,401,815,988 ordinary shares (the “Existing Ordinary Shares”) by 1:2 so that each Existing Ordinary Share was subdivided and reclassified into 1 new ordinary share of £0.000025 each (the “New Ordinary Shares”) and 1 deferred share of £0.009975 each (the “Deferred Shares”), followed by a consolidation of the New Ordinary Shares by 400:1 so that every 400 New Ordinary Shares were consolidated into 1 New Ordinary Share of £0.01 each (the “Capital Reorganisation”).

Investors and stakeholders of Hemogenyx Pharmaceuticals can now look forward to this exciting development as the Company welcomes the issuance of new ordinary shares and a fresh ISIN. This move not only reflects the growth and expansion of the Company but also signals a new chapter in its journey towards developing cutting-edge therapies for blood diseases.

How this will affect me?

As an investor, the admission of new ordinary shares and the issuance of a fresh ISIN can potentially bring about positive changes in your investment portfolio. With the Company’s focus on developing innovative therapies for blood diseases, this move could lead to advancements in medical treatments and potentially increase the value of your investment in Hemogenyx Pharmaceuticals.

How this will affect the world?

The development of new therapies for blood diseases is crucial in improving healthcare worldwide. Hemogenyx Pharmaceuticals’ commitment to innovation and research in this field can have a significant impact on global health outcomes. By welcoming new ordinary shares and a fresh ISIN, the Company is paving the way for advancements in the treatment of various blood disorders, ultimately benefiting patients around the world.

Conclusion

In conclusion, the admission of new ordinary shares and a fresh ISIN by Hemogenyx Pharmaceuticals PLC heralds a new era of growth and innovation for the Company. This strategic move not only reflects Hemogenyx Pharmaceuticals’ commitment to advancing medical treatments for blood diseases but also has the potential to create positive impacts for investors and the global healthcare community. As we unlock the future with these developments, we look forward to witnessing the positive changes that Hemogenyx Pharmaceuticals will bring to the world of biopharmaceuticals.